Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK

被引:17
作者
Roze, Stephane [1 ]
Buompensiere, Maria Ida [2 ]
Ozdemir, Zeynep [2 ]
de Portu, Simona [2 ]
Cohen, Ohad [2 ]
机构
[1] Vyoo Agcy, Lyon, France
[2] Medtron Int Trading Sarl, Tolochenaz, Switzerland
关键词
Cost; cost-effectiveness; type; 1; diabetes; hybrid closed-loop system; continuous subcutaneous insulin infusion; UK; SEVERE HYPOGLYCEMIC EVENTS; DELIVERY-SYSTEM; PUMP THERAPY; IMPACT; INTERVENTIONS; ADOLESCENTS; VALIDATION; MANAGEMENT; MELLITUS; OUTCOMES;
D O I
10.1080/13696998.2021.1939706
中图分类号
F [经济];
学科分类号
02 ;
摘要
Aims The MiniMed 670 G insulin pump system is the first commercially available hybrid closed-loop (HCL) insulin delivery system and clinical studies have shown that this device is associated with incremental benefits in glycemic control relative to continuous subcutaneous insulin infusion (CSII) with or without continuous glucose monitoring (CGM). The aim was to evaluate the long-term cost-effectiveness of the MiniMed 670 G system versus CSII alone in people with type 1 diabetes (T1D) in the UK. Materials and methods Cost-effectiveness analysis was performed using the IQVIA CORE Diabetes Model. Clinical input data were sourced from a clinical trial of the MiniMed 670 G system in 124 adults and adolescents with T1D. The analysis was performed over a lifetime time horizon and both future costs and clinical outcomes were discounted at 3.5% per annum. The analysis was performed from a healthcare payer perspective. Results The use of the MiniMed 670 G system led to an improvement in quality-adjusted life expectancy of 1.73 quality-adjusted life years (QALYs), relative to CSII. Total lifetime direct costs were GBP 35,425 higher with the MiniMed 670 G system than with CSII resulting in an incremental cost-effectiveness ratio (ICER) of GBP 20,421 per QALY gained. Sensitivity analyses revealed that the ICER was sensitive to assumptions around glycemic control and assumptions relating to the quality-of-life benefit associated with a reduction in fear of hypoglycemia. Limitations Long-term projections from short-term data are inherently associated with uncertainty but represent arguably the best available evidence in lieu of long-term clinical trials. Conclusions In the UK, over patient lifetimes, the incremental clinical benefits associated with the use of MiniMed 670 G system means that it is likely to be cost-effective relative to the continued use of CSII in people with T1D, particularly for those with a fear of hypoglycemia or poor baseline glycemic control.
引用
收藏
页码:883 / 890
页数:8
相关论文
共 50 条
  • [21] Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial
    Azahaf, Salima
    Beunen, Kaat
    Van Wilder, Nancy
    Ballaux, Dominique
    Vanhaverbeke, Gerd
    Taes, Youri
    Aers, Xavier-Philippe
    Nobels, Frank
    Van Huffel, Liesbeth
    Marlier, Joke
    Lee, Dahae
    Cuypers, Joke
    Preumont, Vanessa
    Siegelaar, Sarah E.
    Painter, Rebecca C.
    Laenen, Annouschka
    Gillard, Pieter
    Mathieu, Chantal
    Luyten, Jeroen
    Benhalima, Katrien
    ECLINICALMEDICINE, 2025, 81
  • [22] Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security
    Doubova, Svetlana V.
    Roze, Stephane
    Ferreira-Hermosillo, Aldo
    Perez-Cuevas, Ricardo
    Gasca-Pineda, Ricardo
    Barsoe, Casper
    Baran, Jonathan
    Ichihara, Brian
    Gryzbowski, Erick
    Jones, Kyla
    Valencia, Juan E.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (01)
  • [23] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    DIABETES OBESITY & METABOLISM, 2014, 16 (04) : 366 - 375
  • [24] Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control
    Senn, Jon-Duri
    Fischli, Stefan
    Slahor, Lea
    Schelbert, Susanne
    Henzen, Christoph
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03)
  • [25] Continuous Subcutaneous Insulin Infusion Characteristics in Type 1 Diabetes Children and Adolescents in Qatar
    Petrovski, Goran
    Al Khalaf, Fawziya
    Hussain, Khalid
    Campbell, Judith
    El Awwa, Ahmed
    DIABETES THERAPY, 2018, 9 (05) : 2091 - 2098
  • [26] A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden
    J. Jendle
    M. I. Buompensiere
    A. L. Holm
    S. de Portu
    S. J. P. Malkin
    O. Cohen
    Diabetes Therapy, 2022, 13 : 1125 - 1129
  • [27] A national survey on the efficacy and safety of continuous subcutaneous insulin infusion in patients with type 1 diabetes in Spain
    Beato-Vibora, Pilar
    Chico-Ballesteros, Ana
    Gimenez, Marga
    Guerrero-Vazquez, Raquel
    Barrio-Castellanos, Raquel
    Jose Goni-Iriarte, Maria
    Diaz-Soto, Gonzalo
    Francisco Merino-Torres, Juan
    Moreno-Fernandez, Jesus
    Asuncion Martinez-Brocca, Maria
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 137 : 56 - 63
  • [28] Cost-Effectiveness of Closed-Loop Automated Insulin Delivery Using the Cambridge Hybrid Algorithm in Children and Adolescents with Type 1 Diabetes: Results from a Multicenter 6-Month Randomized Trial
    Fox, D. Steven
    Ware, Julia
    Boughton, Charlotte K.
    Allen, Janet M.
    Wilinska, Malgorzata E.
    Tauschmann, Martin
    Denvir, Louise
    Thankamony, Ajay
    Campbell, Fiona
    Wadwa, R. Paul
    Buckingham, Bruce A.
    Davis, Nikki
    Dimeglio, Linda A.
    Mauras, Nelly
    Besser, Rachel E. J.
    Ghatak, Atrayee
    Weinzimer, Stuart A.
    Kanapka, Lauren
    Kollman, Craig
    Sibayan, Judy
    Beck, Roy W.
    Hood, Korey K.
    Hovorka, Roman
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [29] Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands
    Serne, Erik H.
    Roze, Stephane
    Buompensiere, Maria, I
    Valentine, William J.
    de Portu, Simona
    de Valk, Harold W.
    ADVANCES IN THERAPY, 2023, 40 (05) : 2545 - 2548
  • [30] Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis
    Kaur, Harsahiba
    Schneider, Nicole
    Pyle, Laura
    Campbell, Kristen
    Akturk, Halis K.
    Shah, Viral N.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (12) : 736 - 739